Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eteplirsen in Early Stage Duchenne Muscular Dystrophy
NCT02420379Phase 2Completed
- Sponsor
- Sarepta Therapeutics
- Start
- Jun 2015
- Primary completion
- Dec 2018
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of eteplirsen in Duchenne muscular dystrophy (DMD), sponsored by Sarepta Therapeutics. Started Jun 2015; status: completed.
02
Drugs
eteplirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02420379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02420379.